Therion Biologics

Therion Biologics
Based: Cambridge, MA
Founded: 1991

Why It's Fierce: It's show time for Therion. The FDA has OK'd a pivotal Phase III trial of its lead vaccine candidate, Panvac, an experimental treatment for metastatic pancreatic cancer in patients who have failed treatment with gemcitabine. The trial -- involving 250 patients with advanced pancreatic cancer -- is proceeding under a Special Protocol Assessment, which is likely to speed up assessment of a marketing application. Its primary goal is to improve the survival rate of patients compared with supportive care and chemo.

What to look for: Therion's second vaccine candidate, Prostvac-VF, is currently in Phase II clinical trials for the treatment of prostate cancer.

Therion Biologics

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.